Are You Looking for a Top Momentum Pick? Why Supernus Pharmaceuticals (SUPN) is a Great Choice
Does Supernus Pharmaceuticals (SUPN) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks·11d ago
More News
Supernus Pharmaceuticals, Inc. (SUPN) Hit a 52 Week High, Can the Run Continue?
Supernus (SUPN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Zacks·13d ago
Biogen Gets EU Nod for First Postpartum Depression Drug
BIIB secures EU approval for Zurzuvae, the first oral treatment for postpartum depression, boosting its long-term growth prospects.
Zacks·18d ago
Supernus (SUPN) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
While the top- and bottom-line numbers for Supernus (SUPN) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Zacks·2mo ago
Supernus Pharmaceuticals (SUPN) Surpasses Q2 Earnings and Revenue Estimates
Supernus (SUPN) delivered earnings and revenue surprises of +93.62% and +7.34%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·2mo ago
Biogen's Q2 Earnings & Sales Beat, 2025 Outlook Raised, Stock Up
BIIB posts Q2 earnings and sales beat, lifts 2025 outlook on new drug growth and displays resilient MS performance.
Zacks·2mo ago
Biogen Gears Up to Report Q2 Earnings: Here's What to Expect
Biogen's Q2 results may show MS drug declines partially offset by gains from newer drugs.
Zacks·2mo ago
Sage Therapeutics Stock: JPMorgan Sees 8% Downside After Supernus Buyout Terms
Analysts have also noted that the relatively low breakup fee may leave room for a competing offer, possibly from Biogen.
Stocktwits·4mo ago
Supernus Pharmaceuticals Gets Retail Excited Over $795M Acquisition Plan For Sage Therapeutics
Under the terms of the deal, Supernus is looking to acquire Sage for a total consideration of $12 per share in cash.
Stocktwits·4mo ago
Is the Options Market Predicting a Spike in Supernus Pharmaceuticals (SUPN) Stock?